Neuroimmune Interactions, Demyelination Pathways, and Axonal Degeneration in Chronic Inflammatory Demyelinating Polyneuropathy: Evolving Concepts in Biomarkers, IVIg Resistance, and Personalized Treatment Approaches

1.1 Overview of CIDP Pathobiology

Chronic Inflammatory Demyelinating Polyneuropathy is a chronic immune-mediated disorder of the peripheral nervous system characterized by progressive or relapsing sensorimotor dysfunction associated with demyelination and, in advanced disease, secondary axonal degeneration. The disorder is considered the chronic counterpart of Guillain–Barré Syndrome, although its pathogenesis is increasingly recognized as more heterogeneous and mechanistically diverse (Mathey et al., 2015; Van den Bergh et al., 2021). Epidemiological studies estimate the prevalence of CIDP at approximately 1–9 cases per 100,000 individuals, with incidence increasing with age and showing a slight male predominance (Laughlin et al., 2009; Broers et al., 2019). Disease burden is substantial due to chronic disability, impaired mobility, neuropathic pain, fatigue, and frequent long-term dependence on immunomodulatory treatment. In refractory cases, delayed diagnosis and inadequate treatment can contribute to irreversible axonal loss and permanent functional deficits (Koller et al., 2005). CIDP includes both typical and atypical variants. Typical CIDP presents with symmetrical proximal and distal weakness, sensory dysfunction, and reduced tendon reflexes. Atypical forms include distal acquired demyelinating symmetric neuropathy (DADS), multifocal acquired demyelinating sensory and motor neuropathy (MADSAM or Lewis–Sumner syndrome), pure sensory CIDP, and pure motor variants, each potentially associated with distinct pathogenic mechanisms and therapeutic responses (Van den Bergh et al., 2021). The immune-mediated basis of CIDP involves both cellular and humoral immune responses directed against peripheral nerve components. Early models emphasized macrophage-mediated myelin stripping, whereas newer evidence supports complex interactions involving autoreactive T cells, pathogenic B cells, complement activation, and nodal/paranodal autoimmunity (Dalakas, 2011; Mathey et al., 2015).

1.2 Cellular Immune Dysregulation

Cellular immune dysfunction is central to CIDP pathogenesis. Dysregulated T-cell subsets, particularly imbalance between pro-inflammatory T helper populations and regulatory T cells (Tregs), have been implicated in sustaining chronic peripheral nerve inflammation. Increased Th1- and Th17-mediated responses promote production of inflammatory cytokines including interferon-γ (IFN-γ) and interleukin-17 (IL-17), which contribute to macrophage recruitment and demyelinating injury (Chi et al., 2010; Li et al., 2014). Macrophages are major effectors of nerve injury in CIDP. Histopathological studies demonstrate macrophage penetration through Schwann cell basal lamina with active stripping of compact myelin, a hallmark of segmental demyelination. Activated macrophages release reactive oxygen species, proteases, and inflammatory mediators that amplify tissue damage and may contribute to secondary axonal degeneration (Dalakas, 2011). B cells also play a critical pathogenic role. Beyond antibody production, B cells function as antigen-presenting cells and cytokine-producing immune regulators. Autoantibodies directed against nodal and paranodal proteins such as contactin-1 and neurofascin-155 define mechanistically distinct CIDP subsets, often associated with severe disease and poor response to intravenous immunoglobulin (IVIg) (Querol et al., 2014; Doppler et al., 2016). Antigen-presenting cells, including dendritic cells and macrophages, facilitate peripheral nerve inflammation through antigen processing and activation of autoreactive T cells. This antigen-driven immune amplification promotes chronic neuroimmune activation and persistent demyelination (Mathey et al., 2015).

1.3 Cytokines, Chemokines, and Inflammatory Signaling

Pro-inflammatory cytokine networks contribute significantly to disease perpetuation in CIDP. Elevated levels of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), IL-17, and IFN-γ have been reported in serum, cerebrospinal fluid, and nerve tissues of affected patients (Chi et al., 2010). These cytokines enhance immune cell recruitment, endothelial activation, and inflammatory injury within peripheral nerves. TNF-α contributes to Schwann cell dysfunction and myelin injury, whereas IL-6 promotes B-cell activation and chronic inflammation. IL-17 has been implicated in blood–nerve barrier disruption and increased leukocyte infiltration. IFN-γ enhances macrophage-mediated cytotoxicity, linking adaptive and innate immune responses (Li et al., 2014). Complement activation represents another major inflammatory pathway. Deposition of complement components at sites of nerve injury and antibody-mediated complement fixation may drive demyelination, particularly in antibody-associated CIDP variants (Dalakas, 2011). Activation of inflammatory cascades involving NF-κB and related signaling pathways may further sustain chronic disease progression. Neuroimmune crosstalk between immune cells, Schwann cells, axons, and endoneurial endothelial cells creates a self-amplifying inflammatory microenvironment. Chronic activation of this neuroimmune network may help explain progression from reversible inflammatory dysfunction to irreversible neurodegeneration (Mathey et al., 2015).

1.4 Nodal and Paranodal Autoimmunity

A major conceptual advance in CIDP has been recognition of autoimmune disorders targeting nodes of Ranvier and paranodes. Autoantibodies against contactin-1 (CNTN1), neurofascin-155 (NF155), and contactin-associated protein-1 (Caspr1) disrupt axoglial interactions essential for saltatory conduction (Querol et al., 2014; Doppler et al., 2016). Unlike classical macrophage-mediated demyelination, nodal/paranodal autoimmunity may produce conduction failure through structural disorganization without overt segmental demyelination. Antibody-mediated detachment of paranodal loops and disruption of sodium channel clustering can cause severe neurological dysfunction (Doppler et al., 2016). These autoantibody-positive patients frequently represent distinct immunological subtypes characterized by younger onset, tremor, sensory ataxia, aggressive disease course, and reduced response to IVIg. Some demonstrate better responses to B-cell–depleting therapy such as Rituximab, supporting precision treatment strategies (Querol et al., 2014). Recognition of these mechanistically distinct subgroups has shifted CIDP from a single disorder concept toward a spectrum of immune-mediated neuropathies requiring individualized classification and management (Van den Bergh et al., 2021).

1.5 Blood–Nerve Barrier Dysfunction

The blood–nerve barrier (BNB) plays a critical protective role in maintaining peripheral nerve immune privilege. Increasing evidence suggests BNB dysfunction contributes significantly to CIDP pathogenesis by allowing infiltration of circulating immune cells and inflammatory mediators (Kanda, 2013). Inflammatory cytokines and endothelial activation can increase BNB permeability, promoting leukocyte migration into endoneurial spaces. Upregulation of adhesion molecules such as ICAM-1 and VCAM-1 facilitates immune cell trafficking into peripheral nerves (Kanda, 2013). Endothelial injury may also contribute to altered microvascular homeostasis, impaired nutrient delivery, and oxidative stress, further exacerbating nerve injury. Persistent barrier dysfunction can reinforce chronic inflammation and contribute to ongoing demyelination and axonal degeneration. Importantly, BNB disruption may have implications for both biomarker development and therapeutic response. Barrier integrity may influence penetration of immunotherapies, disease severity, and progression risk, making it a potential target for future intervention (Mathey et al., 2015).

2. Demyelination and Axonal Degeneration Pathways

2.1 Molecular Mechanisms of Segmental Demyelination

Segmental demyelination is a defining pathological hallmark of Chronic Inflammatory Demyelinating Polyneuropathy and reflects immune-mediated disruption of myelin integrity without immediate primary axonal transection. In CIDP, demyelination results from coordinated injury involving Schwann cell dysfunction, direct myelin protein damage, and complement-mediated inflammatory injury (Dalakas, 2011; Mathey et al., 2015).

2.1.1 Schwann Cell Dysfunction

Schwann cells are central to peripheral myelin maintenance, trophic support, and axonal metabolic coupling. In CIDP, inflammatory cytokines such as TNF-α, IL-1β, and IFN-γ alter Schwann cell homeostasis, promoting dedifferentiation, impaired remyelination, and susceptibility to immune attack (Kieseier et al., 2002). Activated macrophages infiltrate peripheral nerves and initiate “myelin stripping,” penetrating Schwann cell basal lamina and physically removing compact myelin layers (Dalakas, 2011). Schwann cell dysfunction also involves altered expression of myelin-associated proteins, reduced production of trophic mediators, and metabolic stress that impairs regenerative remyelination. Persistent injury may lead to onion bulb formation due to repeated demyelination–remyelination cycles, a histopathological marker of chronic disease (Mathey et al., 2015).

2.1.2 Myelin Protein Damage

Structural damage to major myelin proteins including peripheral myelin protein-22 (PMP22), myelin protein zero (P0), and myelin basic protein contributes to destabilization of myelin architecture (Koller et al., 2005). Immune-mediated disruption may occur through antibody-associated targeting, inflammatory protease activity, or indirect injury secondary to macrophage-mediated degradation. Damage to myelin proteins compromises insulation and disrupts action potential propagation. This promotes conduction slowing, temporal dispersion, and conduction block—electrophysiological signatures of CIDP (Van den Bergh et al., 2021).

2.1.3 Complement-Mediated Myelin Injury

Complement activation is increasingly recognized as a major contributor to demyelinating injury. Autoantibody-mediated activation of classical complement pathways can generate membrane attack complexes, promote inflammatory amplification, and facilitate macrophage recruitment (Dalakas, 2011). Complement deposition may be especially relevant in nodal/paranodal antibody-associated disease, where immune-mediated injury may involve structural disruption rather than classical macrophage-driven demyelination (Querol et al., 2014). Persistent complement activation may convert potentially reversible inflammatory dysfunction into irreversible neurodegenerative injury.

2.2 Mechanisms of Secondary Axonal Loss

Although demyelination initiates disease in many patients, long-term disability in CIDP often correlates more strongly with secondary axonal degeneration (Mathey et al., 2015).

2.2.1 Mitochondrial Dysfunction

Axons rely on intact mitochondrial bioenergetics to sustain ion gradients, transport systems, and structural maintenance. Chronic demyelination increases metabolic demand due to redistribution of sodium channels and heightened ATP consumption, contributing to mitochondrial overload and dysfunction (Waxman, 2006). Mitochondrial impairment leads to ATP depletion, calcium dysregulation, and activation of pro-degenerative pathways. These processes contribute to axonal vulnerability and progressive neurodegeneration.

2.2.1 Oxidative Stress Pathways

Inflammation-driven reactive oxygen species and nitric oxide species can damage lipids, proteins, and mitochondrial DNA, promoting oxidative injury (Kieseier et al., 2002). Oxidative stress may amplify both demyelination and secondary axonal injury. Persistent oxidative injury also contributes to chronic neurodegenerative signaling involving apoptosis-associated pathways, stress kinases, and inflammatory feedback loops.

2.2.3 Neurofilament Disruption and Axonal Transport Failure

Axonal integrity depends on neurofilament organization and efficient axonal transport. Chronic inflammatory stress can disrupt cytoskeletal stability, impair microtubule-mediated transport, and reduce delivery of essential organelles and proteins to distal axons (Petzold, 2005). Elevated serum and cerebrospinal fluid neurofilament light chain, an emerging biomarker of axonal injury, supports the role of cytoskeletal degeneration in CIDP progression (Bischof et al., 2018).

2.3 Nodal/Paranodal Disorganization and Conduction Failure

Recognition of nodal and paranodal pathology has transformed understanding of conduction dysfunction in CIDP.

2.3.1 Sodium Channel Clustering Defects

Nodes of Ranvier depend on highly organized sodium channel clustering for saltatory conduction. Autoimmune disruption involving antibodies against Contactin-1, Neurofascin-155, and Caspr1 may destabilize nodal architecture (Querol et al., 2014; Doppler et al., 2016). Disorganized sodium channel clustering can produce conduction block independent of classical segmental demyelination.

2.3.2 Saltatory Conduction Impairment

Disruption of axoglial junctions impairs saltatory conduction by altering ion channel distribution and electrical insulation. Functional conduction failure may occur before irreversible structural degeneration develops (Doppler et al., 2016).

2.3.3 Reversible vs Irreversible Injury Models

An important conceptual distinction exists between reversible nodal dysfunction (“nodopathy”) and irreversible axonal degeneration. Early inflammatory conduction failure may respond to immunotherapy, whereas persistent structural disorganization may progress to fixed disability (Mathey et al., 2015).

2.4 Chronic Neurodegeneration in Refractory CIDP

2.4.1 Transition from Inflammation to Neurodegeneration

In treatment-refractory CIDP, disease may evolve from primarily inflammatory demyelination toward chronic neurodegenerative pathology. Persistent immune activation, oxidative stress, mitochondrial dysfunction, and structural disconnection may drive this transition (Dalakas, 2011).

2.4.2 Structural Correlates of Disability Progression

Progressive disability correlates with axonal loss, reduced nerve fiber density, chronic denervation, and muscle wasting. Imaging and electrophysiological studies increasingly support structural correlates of long-term functional deterioration (Van den Bergh et al., 2021).

2.4.3 Neurodegenerative Signaling Pathways

Potential pathways implicated include calcium-mediated degeneration, stress kinase activation, mitochondrial permeability transition signaling, and chronic inflammatory neurotoxicity. These mechanisms may represent therapeutic targets beyond immunosuppression.

2.5 Experimental Models and Translational Insights

2.5.1 Animal and Ex Vivo Models of CIDP

Experimental autoimmune neuritis (EAN) remains the principal animal model for immune-mediated demyelinating neuropathy. EAN reproduces T-cell–mediated inflammation, macrophage infiltration, and demyelination, offering mechanistic insight into immune injury (Hartung et al., 1995). Ex vivo nerve models have further enabled study of complement injury, antibody-mediated nodopathy, and Schwann cell responses.

2.5.2 Lessons from Guillain–Barré Syndrome and Related Neuropathies

Comparative studies with Guillain–Barré Syndrome provide insight into shared mechanisms of inflammatory demyelination, complement injury, and axonal degeneration, while highlighting differences between acute and chronic disease states (Yuki & Hartung, 2012).

2.5.3 Translational Relevance to Human Disease

Experimental models support emerging translational strategies involving complement inhibitors, neuroprotective therapies, remyelination-enhancing approaches, and precision therapies targeting nodal autoimmunity.

Table 1. Major Pathways Linking Demyelination and Axonal Degeneration in CIDP

3. Emerging Biomarkers for Diagnosis, Prognosis, and Disease Stratification

3.1 Serological and Immunological Biomarkers

Biomarker discovery in Chronic Inflammatory Demyelinating Polyneuropathy has advanced substantially as the disorder has increasingly been understood as a heterogeneous immune-mediated neuropathy rather than a single uniform disease entity. Traditional diagnosis has relied heavily on clinical and electrophysiological criteria, but emerging serological and immunological biomarkers are improving mechanistic classification, prognostic evaluation, and therapeutic selection (Van den Bergh et al., 2021; Mathey et al., 2015).

3.1.1 Autoantibody Signatures

One of the most important developments in CIDP biomarker research has been identification of autoantibodies directed against nodal and paranodal proteins. Antibodies against Neurofascin-155, Contactin-1, and Caspr1 have defined immunologically distinct subgroups associated with severe disease, sensory ataxia, tremor, and frequent resistance to intravenous immunoglobulin (IVIg) (Querol et al., 2014; Doppler et al., 2016).

These antibodies may serve not only as diagnostic markers but also as predictive biomarkers for treatment response. Patients with IgG4-mediated paranodal autoimmunity often respond poorly to IVIg but may respond better to B-cell–targeted therapies such as Rituximab (Querol et al., 2014).

Autoantibody profiling has therefore become increasingly relevant for biomarker-driven patient subtyping.

3.1.2 Cytokine and Chemokine Profiles

Inflammatory cytokine signatures have also emerged as potential biomarkers of disease activity. Elevated circulating or cerebrospinal fluid levels of TNF-α, IL-6, IL-17, IFN-γ, CXCL13, and related mediators have been associated with immune activation and inflammatory burden in CIDP (Chi et al., 2010; Li et al., 2014). Chemokines involved in leukocyte recruitment may reflect ongoing inflammatory trafficking into peripheral nerves and may have utility as markers of active disease versus remission.

3.1.3 Complement-Related Markers

Complement pathway dysregulation is increasingly recognized in CIDP pathogenesis. Elevated complement activation fragments and markers of terminal complement activation may identify patients with complement-driven immune injury (Dalakas, 2011). Such biomarkers may also have future predictive value for selecting patients likely to benefit from complement-targeted therapies.

3.2 Neurodegeneration Biomarkers

Although immune biomarkers reflect inflammatory mechanisms, neurodegeneration biomarkers may better capture structural injury and long-term disability risk.

3.2.1 Neurofilament Light Chain (NfL)

Neurofilament Light Chain has emerged as one of the most promising biomarkers of axonal injury in CIDP. Elevated serum and cerebrospinal fluid NfL levels correlate with neuroaxonal damage, disease severity, and potentially treatment response (Bischof et al., 2018).

Because disability progression in CIDP often reflects cumulative axonal injury rather than inflammation alone, NfL may be particularly valuable for prognosis and longitudinal monitoring.

3.2.2 Glial and Axonal Injury Markers

Additional markers under investigation include glial fibrillary acidic protein (GFAP), markers of Schwann cell stress, and structural proteins released during axonal injury (Petzold, 2005).

These may help distinguish active inflammatory injury from chronic neurodegenerative progression.

3.2.3 Proteomic and Metabolomic Candidates

Proteomic profiling has identified potential signatures involving immune proteins, complement components, and neurodegeneration-associated pathways (Stojkovic et al., 2019).

Metabolomic approaches have further suggested candidate biomarkers related to mitochondrial dysfunction, oxidative stress, and altered energy metabolism. Although still investigational, these may contribute to future multidimensional biomarker panels.

3.3 Electrophysiological and Imaging Biomarkers

Electrophysiology remains central to diagnosis but increasingly serves broader biomarker roles in prognosis and stratification.

3.3.1 Nerve Conduction Parameters

Electrophysiological abnormalities including slowed conduction velocity, prolonged distal latencies, conduction block, and temporal dispersion remain foundational biomarkers in CIDP diagnosis (Van den Bergh et al., 2021).

Beyond diagnosis, quantitative electrophysiological measures may reflect disease severity, monitor progression, and predict treatment responsiveness.

3.3.2 MRI Neurography Findings

Magnetic Resonance Neurography and peripheral nerve imaging have identified hypertrophy, inflammatory nerve enlargement, and structural abnormalities associated with CIDP (Kerasnoudis & Pitarokoili, 2020). MRI biomarkers may help distinguish inflammatory neuropathy from mimics and may contribute to longitudinal disease monitoring.

3.3.3 Ultrasound-Based Biomarkers

Peripheral nerve ultrasound has emerged as a promising non-invasive biomarker tool. Increased cross-sectional area, fascicular abnormalities, and nerve enlargement may correlate with inflammatory activity and disease subtype (Kerasnoudis & Pitarokoili, 2020). Ultrasound-based measures may also provide practical tools for repeated monitoring.

3.4 CSF and Molecular Biomarkers

3.4.1 Cerebrospinal Fluid Protein Signatures

Elevated cerebrospinal fluid (CSF) protein remains a classical supportive finding in CIDP, but newer approaches seek more specific CSF biomarker signatures (Koller et al., 2005). Proteomic profiling has identified candidate inflammatory and neurodegeneration-related proteins that may improve diagnostic specificity.

3.4.2 Transcriptomics and Epigenetic Markers

Transcriptomic approaches have revealed altered immune-related gene expression patterns in CIDP, including pathways involving T-cell activation, inflammatory signaling, and immune regulation (Mathey et al., 2015). Epigenetic mechanisms, including microRNA dysregulation and DNA methylation changes, may provide novel biomarkers linked to disease activity or treatment response.

3.4.3 Multi-Omics Approaches

Integrated multi-omics strategies combining genomics, proteomics, metabolomics, and transcriptomics may offer systems-level characterization of CIDP heterogeneity. These approaches may help identify composite biomarker signatures that outperform individual markers.

3.5 Biomarker-Guided Disease Stratification

A major emerging goal is moving beyond single biomarkers toward biomarker-guided stratification models.

3.5.1 Predictors of Disease Severity

Potential severity predictors include elevated NfL, paranodal autoantibody positivity, severe electrophysiological abnormalities, and imaging evidence of structural nerve injury (Bischof et al., 2018; Van den Bergh et al., 2021). Combining these variables may improve risk assessment.

3.5.2 Prognostic Models

Multivariable prognostic models integrating clinical phenotype, biomarkers, electrophysiology, and imaging may enable prediction of relapse risk, treatment dependency, and long-term disability progression. Such models remain under development but represent a major step toward precision neurology.

3.5.3 Biomarker-Driven Patient Subtyping

Perhaps the most transformative application of biomarkers is mechanistic patient subtyping. Rather than viewing CIDP as a single disorder, patients may be classified into inflammatory-dominant, nodopathy-dominant, complement-mediated, or neurodegeneration-predominant subtypes. This approach could support individualized treatment selection, including IVIg, corticosteroids, plasma exchange, B-cell–directed therapies, or emerging targeted interventions.

Table 2. Emerging Biomarkers in CIDP: Diagnostic, Prognostic, and Stratification Roles

4. Mechanisms of IVIg Resistance and Therapeutic Challenges

4.1 Current Role of IVIg in CIDP Management

Intravenous Immunoglobulin remains a cornerstone therapy for Chronic Inflammatory Demyelinating Polyneuropathy and is widely used as first-line treatment alongside corticosteroids and plasma exchange. Its clinical value lies in rapid immunomodulatory effects, relatively favorable safety profile, and demonstrated efficacy in induction and maintenance treatment, including relapse prevention in responsive patients (Dalakas, 2011; Van den Bergh et al., 2021).

4.1.1 Mechanisms of IVIg Action

IVIg exerts pleiotropic immunomodulatory effects rather than acting through a single dominant mechanism. Proposed actions include neutralization of pathogenic autoantibodies, modulation of Fc receptor signaling, inhibition of complement-mediated injury, suppression of pro-inflammatory cytokines, expansion of regulatory T-cell function, and interference with antigen presentation (Kazatchkine & Kaveri, 2001; Dalakas, 2011). One important mechanism involves saturation or modulation of Fc gamma receptors on macrophages, reducing antibody-mediated inflammatory effector activity. IVIg may also contain anti-idiotypic antibodies capable of neutralizing pathogenic autoantibodies. In addition, inhibition of complement deposition may reduce inflammatory damage at myelin, nodal, or paranodal structures.

4.1.2 Clinical Efficacy and Limitations

Clinical trials, including the landmark ICE trial, established IVIg efficacy in improving strength and disability in CIDP (Hughes et al., 2008). However, important limitations remain.

Not all patients respond adequately, some develop partial or transient responses, and others require long-term repeated infusions with dose dependency. Chronic exposure raises issues involving cost, logistics, fluctuating response, and incomplete prevention of progressive axonal injury.

These limitations have prompted major interest in understanding biological mechanisms underlying IVIg resistance.

4.2 Immunological Basis of IVIg Resistance

Resistance to IVIg is increasingly viewed not as simple treatment failure, but as a mechanistically heterogeneous phenomenon involving multiple immune pathways.

4.2.1 Fc Receptor-Related Mechanisms

Variation in Fc receptor biology may influence therapeutic responsiveness. Abnormal Fcγ receptor expression or signaling may impair the immunomodulatory effects of IVIg, particularly its regulation of macrophage-mediated inflammatory activity (Kazatchkine & Kaveri, 2001). Differences in Fc-mediated immune regulation may partly explain inter-patient variability in response.

4.2.2 Complement Persistence

Persistent complement activation may contribute to inadequate IVIg response, particularly where complement-mediated injury remains dominant despite treatment (Dalakas, 2011). Patients with ongoing complement-driven pathology may require therapies specifically targeting complement pathways rather than relying solely on broad immunomodulation.

4.2.3 Autoantibody-Associated Treatment Failure

A major recognized cause of IVIg resistance involves nodal/paranodal autoantibody-associated disease. Patients with antibodies against Neurofascin-155, Contactin-1, or Caspr1 frequently show poor IVIg responsiveness (Querol et al., 2014; Doppler et al., 2016). In these patients, IgG4-mediated autoimmune mechanisms may be relatively insensitive to classical IVIg effects, supporting use of alternative targeted approaches.

4.3 Clinical Predictors of Poor Response

Identifying predictors of poor response is essential for earlier treatment optimization.

4.3.1 Phenotypic Predictors

Clinical phenotypes associated with reduced IVIg responsiveness may include aggressive disease course, severe sensory ataxia, tremor, predominant axonal injury, and atypical CIDP subtypes linked to nodal/paranodal pathology (Van den Bergh et al., 2021). Patients with longstanding disease and advanced structural nerve injury may also show diminished reversibility.

4.3.2 Biomarker Predictors

Emerging biomarker predictors include autoantibody positivity, elevated Neurofilament Light Chain suggesting axonal injury, complement-related markers, and imaging evidence of structural nerve damage (Bischof et al., 2018). Biomarker integration may help identify patients unlikely to benefit from repeated empiric IVIg escalation.

4.3.3 Treatment-Refractory Subgroups

Treatment-refractory CIDP likely includes biologically distinct subgroups rather than a uniform resistant population. These may include:

• Nodopathy/paranodopathy-dominant disease
• Complement-mediated variants
• Neurodegeneration-predominant disease
• Chronic immune phenotypes requiring alternative pathway targeting

Recognition of these subgroups is central to precision therapy.

4.4 Alternative and Emerging Therapeutic Strategies

Growing recognition of IVIg resistance has accelerated development of alternative therapies.

4.4.1 Corticosteroids and Plasma Exchange

Prednisone and related corticosteroids remain established alternatives, particularly in IVIg nonresponders. Plasma exchange can provide rapid benefit through removal of pathogenic antibodies and immune mediators (Van den Bergh et al., 2021). However, long-term toxicity and logistical challenges limit broad dependence on these approaches.

4.4.2 Rituximab and B-Cell Targeted Therapies

Rituximab has shown promise particularly in autoantibody-associated or refractory CIDP. Its rationale is strongest in B-cell–driven disease or IgG4-mediated nodopathy (Querol et al., 2014). Additional B-cell pathway therapies are under investigation.

4.4.3 Complement Inhibitors

Complement inhibition represents an important emerging strategy. Agents targeting C5 or related complement pathways may be particularly relevant in complement-mediated inflammatory injury. Examples include Eculizumab and newer pathway-directed agents under study.

4.4.4 FcRn Antagonists and Novel Biologics

Therapies targeting the neonatal Fc receptor (FcRn) seek to reduce pathogenic IgG burden through accelerated antibody clearance. Examples include Efgartigimod and related emerging biologics. These approaches may be particularly relevant where pathogenic antibody burden drives disease.

4.5 Precision Approaches to Overcome Resistance

A major paradigm shift is moving from empiric escalation toward mechanism-guided therapy.

4.5.1 Mechanism-Based Treatment Selection

Rather than treating all IVIg failures similarly, therapeutic selection may increasingly depend on dominant disease mechanism:

• Macrophage-mediated inflammatory disease → IVIg or corticosteroids
• B-cell/autoantibody-mediated disease → Rituximab-based strategies
• Complement-driven disease → complement inhibitors
• Neurodegeneration-predominant disease → combined immunotherapy plus neuroprotection

This framework aligns therapy with biology.

4.5.2 Adaptive Therapeutic Algorithms

Adaptive treatment algorithms may incorporate dynamic reassessment using clinical response, biomarkers, electrophysiology, and imaging.

A precision algorithm may involve:

1. Initial response assessment
2. Biomarker-based mechanistic stratification
3. Targeted therapeutic adjustment
4. Longitudinal monitoring and adaptation

Such models may reduce ineffective prolonged exposure to suboptimal therapy.

4.5.3 Combination Therapy Strategies

Combination approaches may be required in biologically complex disease.

Potential strategies include:

• IVIg + B-cell–directed therapy
• IVIg + complement inhibition
• Corticosteroid + biologic approaches
• Immunotherapy + neuroprotective adjuncts

Combination approaches may be particularly relevant where overlapping inflammatory and neurodegenerative mechanisms coexist.

Table 3. Mechanisms and Clinical Implications of IVIg Resistance in CIDP

5. Personalized Treatment Approaches and Future Directions

5.1 Precision Medicine Framework in CIDP

The management of Chronic Inflammatory Demyelinating Polyneuropathy is increasingly shifting from empiric immunotherapy toward precision medicine approaches that align treatment with underlying disease biology, patient-specific risk factors, and predicted therapeutic response. This transition reflects growing recognition that CIDP represents a spectrum of immune-mediated neuropathies rather than a single mechanistically uniform disorder (Mathey et al., 2015; Van den Bergh et al., 2021).

5.1.1 Moving Beyond One-Size-Fits-All Treatment

Traditional CIDP management has largely relied on standardized use of Intravenous Immunoglobulin, corticosteroids, and plasma exchange. While effective for many patients, this approach may be suboptimal for individuals with biologically distinct disease mechanisms, including nodal/paranodal autoimmunity, complement-mediated injury, or neurodegeneration-predominant disease (Dalakas, 2011). A precision medicine framework seeks to move beyond generalized treatment algorithms toward individualized mechanistic targeting.

5.1.2 Immunophenotype-Guided Therapy

Immunophenotyping offers a foundation for treatment personalization. Patients may increasingly be classified according to dominant immune mechanisms such as:

• Macrophage-driven inflammatory demyelination
• B-cell/autoantibody-associated nodopathy
• Complement-mediated immune injury
• Chronic neurodegeneration-predominant disease

For example, patients with Neurofascin-155 or Contactin-1 antibodies may benefit from B-cell–directed strategies such as Rituximab rather than conventional IVIg-centered treatment (Querol et al., 2014).

5.1.3 Biomarker-Informed Therapeutic Decisions

Integration of biomarkers such as autoantibodies, complement-related markers, imaging abnormalities, and Neurofilament Light Chain may support treatment selection, escalation decisions, and prediction of therapeutic response (Bischof et al., 2018).

Biomarker-guided treatment models may help minimize ineffective therapy exposure and improve long-term outcomes.

5.2 Individualized Monitoring and Treatment Optimization

Precision therapy requires not only individualized initiation strategies, but individualized monitoring over time.

5.2.1 Longitudinal Response Monitoring

Static treatment decisions may fail to capture evolving disease biology. Longitudinal monitoring may incorporate:

• Serial clinical disability assessment
• Repeated electrophysiological testing
• Biomarker tracking (e.g., NfL trends)
• Peripheral nerve imaging
• Patient-reported outcomes

This approach allows dynamic treatment adaptation rather than fixed protocols.

5.2.2 Relapse Prediction Models

Relapse remains a major challenge in CIDP. Predictive models integrating clinical phenotype, prior treatment dependence, biomarker profiles, and electrophysiological features may improve relapse risk estimation (Van den Bergh et al., 2021).

Future predictive models may support preemptive rather than reactive treatment adjustments.

5.2.3 Dose and Interval Personalization

Optimization of IVIg dosing and interval scheduling is an important personalized strategy. Some patients may benefit from dose reduction, interval extension, or transition to Subcutaneous Immunoglobulin maintenance, whereas others require intensified treatment schedules.

Individualized dosing strategies may improve efficacy, reduce toxicity, and optimize resource utilization.

5.3 Emerging Regenerative and Neuroprotective Strategies

While conventional therapy focuses largely on immune suppression, future management may increasingly incorporate regeneration and neuroprotection.

5.3.1 Remyelination-Promoting Therapies

Strategies aimed at enhancing Schwann cell repair and remyelination may help restore function beyond controlling inflammation.

Potential approaches include:

• Schwann cell regenerative signaling modulation
• Growth factor-based therapies
• Myelin repair–promoting molecular pathways
• Remyelination-enhancing biologics

These strategies remain investigational but represent a major therapeutic frontier.

5.3.2 Axonal Preservation Approaches

Because long-term disability often reflects axonal injury, preserving axonal integrity is increasingly recognized as a therapeutic goal.

Potential neuroprotective strategies include:

• Mitochondrial support approaches
• Oxidative stress reduction
• Cytoskeletal stabilization strategies
• Anti-degenerative pathway targeting

These may be particularly relevant in refractory or progressive disease.

5.3.3 Cell-Based and Gene-Based Strategies

Cell-based therapies, including immunoregulatory cellular approaches and regenerative strategies, are being explored in broader neuroimmunology and may eventually have relevance in CIDP.

Gene-based strategies may also emerge for targeting immune regulation or repair pathways.

5.4 Artificial Intelligence and Predictive Modeling

Artificial intelligence (AI) may play an increasingly important role in precision CIDP management.

5.4.1 Machine Learning for Diagnosis and Prognosis

Machine learning approaches may improve recognition of complex diagnostic patterns integrating:

• Clinical phenotype
• Electrophysiology
• Imaging
• Biomarker signatures
• Longitudinal disease trajectories

These tools may improve both diagnostic accuracy and prognostic modeling.

5.4.2 Digital Biomarkers

Digital biomarkers derived from wearable monitoring, motor performance tracking, gait analysis, and remote symptom monitoring may provide new tools for continuous disease assessment. Potential digital biomarkers could complement conventional clinic-based evaluations.

5.4.3 Clinical Decision Support Tools

AI-enabled decision support systems may assist clinicians in:

• Mechanistic treatment selection
• Predicting IVIg resistance
• Forecasting relapse risk
• Optimizing dose adjustment
• Supporting precision therapeutic algorithms

These approaches remain emerging but align strongly with individualized care models.

5.5 Future Research Priorities and Clinical Translation

5.5.1 Unresolved Mechanistic Questions

Despite advances, major mechanistic questions remain unresolved, including:

• Drivers of treatment resistance
• Determinants of transition from inflammation to neurodegeneration
• Biological basis of disease heterogeneity
• Pathogenic significance of emerging biomarkers
• Mechanisms of remyelination failure

Addressing these gaps is critical for next-generation therapy.

5.5.2 Gaps in Biomarker Validation

Although many candidate biomarkers have been proposed, widespread implementation remains limited by:

• Incomplete validation
• Limited standardization
• Small cohort studies
• Uncertain longitudinal performance
• Inconsistent integration into clinical practice

Large multicenter biomarker validation studies remain a major priority.

5.5.3 Toward Individualized Treatment Pathways

The long-term goal is individualized treatment pathways integrating:

Clinical phenotype

• Immunophenotype
• Biomarkers
• Imaging
• Predictive modeling

This framework may ultimately replace stepwise empiric treatment escalation with biologically informed individualized management.

Table 4. Personalized Treatment Strategies and Future Precision Directions in CIDP